VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis (Q37872779)

24 August 2017

1 reference

title

VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis (English)

1 reference

24 August 2017

0 references

Friedrich Horak

1

1 reference

PubMed ID

21548830

24 August 2017

language of work or name

English

0 references

publication date

9 May 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

1 reference

24 August 2017

20

1 reference

24 August 2017

7

1 reference

24 August 2017

981-986

1 reference

The burden of allergic rhinitis

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Update on the medical treatment of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Overview of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Targeting Toll-like receptors: emerging therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Immunomodulators for allergic respiratory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Toll-like receptor 9 agonists as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.583237

10.1517/13543784.2011.583237

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21548830